title: Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
abstract: OBJECTIVE
  In order to define accurate survival outcome in breast cancer, 10-year follow-up is required and such long-term survival information are few and difficult to gather.
  
  
  METHODS
  We recruited 253 breast cancer patients who undertook operation with no prior chemotherapy. Ten-year survival outcomes were evaluated by clinicopathological factors.
  
  
  RESULTS
  Significant univariate prognostic factors were: T factor, N factor, preoperative values of tumor markers, and biological factors. T-factor, CEA, hormone receptor, and Ki-67 were the final independent prognostic factors of recurrence-free survival through multivariate analysis. The Luminal A group except for the Ki-67-positive cases showed the best survival outcomes, while the HER2-positive or triple-negative (TN) groups showed worse prognosis than the Luminal A group, and Ki-67 was shown to be an excellent prognostic factor in each stage (p<0.01).
  
  
  CONCLUSIONS
  Ki-67 has a great potential as a prognostic biomarker while prognostic information of this sort could be beneficial for development of novel therapeutic strategies.
authors.affiliation: FACS, Department of Surgery, Kitasato University School of Medicine, 1-15-1, Kitasato, Minami-ku, Sagamihara, Japan. gekaw@med.kitasato-u.ac.jp.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nishimiya
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Kosaka
authors.forename: Keishi
authors.initials: K
authors.lastname: Yamashita
authors.forename: Naoko
authors.initials: N
authors.lastname: Minatani
authors.forename: Mariko
authors.initials: M
authors.lastname: Kikuchi
authors.forename: Akira
authors.initials: A
authors.lastname: Ema
authors.forename: Kazunori
authors.initials: K
authors.lastname: Nakamura
authors.forename: Mina
authors.initials: M
authors.lastname: Waraya
authors.forename: Norihiko
authors.initials: N
authors.lastname: Sengoku
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Tanino
authors.forename: Masaru
authors.initials: M
authors.lastname: Kuranami
authors.forename: Masahiko
authors.initials: M
authors.lastname: Watanabe
authors.forename: Watanabe
authors.initials: W
authors.lastname: Masahiko
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D018275:Carcinoma, Lobular / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D019394:Ki-67 Antigen / Q000378:metabolism*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D009367:Neoplasm Staging; D011183:Postoperative Complications; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D015996:Survival Rate; D013997:Time Factors; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
keywords: Breast cancer; chemotherapy-naïve patients; clinicopathological parameters; multivariate analysis